2022年RSV流行高峰期间美国重症监护病房收治的呼吸道合胞病毒(RSV)感染婴儿
这项基于美国27个州39家儿童医院公共卫生前瞻性监测登记的横断面研究,纳入2022年10月17日至12月16日因实验室确诊RSV感染入住重症监护单元≥24小时的600例婴儿。结果中位年龄2.6个月(IQR 1.4-6.0),81.2%无基础疾病,23.8%接受有创机械通气(中位6.0天),4例(0.7%)接受体外膜氧合,2例死亡;非插管婴儿最高呼吸支持为经鼻高流量氧疗(40.5%)。<3月龄、早产(胎龄<37周)或公共保险的婴儿插管风险更高。作者认为需针对所有婴儿的RSV预防干预以减轻重症负担。
要点
- 600例因RSV入住ICU的婴儿中81.2%(487例)无基础疾病,提示重症RSV并非仅见于高危儿。
- 23.8%(143例)接受有创机械通气,中位通气6.0天(IQR 4.0-10.0),幸存者中位住院5天(IQR 4-10)。
- 非插管婴儿最高呼吸支持依次为经鼻高流量氧疗40.5%、双水平正压通气25.0%、持续气道正压通气8.7%,提示ICU呼吸支持以无创为主。
- 4例(0.7%)接受体外膜氧合,2例死亡,提示重症RSV总体致死率低但仍有极端重症。
适用人群与场景
- 美国27个州39家儿童医院中,2022年10月17日至12月16日因实验室确诊RSV感染入住重症监护单元≥24小时的婴儿。
- 每个中心连续纳入前15至20例符合条件的婴儿,目标样本量600例。
诊断标准与关键阈值
- 实验室确诊RSV感染,且入住提供重症监护的单元≥24小时。
红旗征与不能漏的情况
- <3月龄、早产(胎龄<37周)或公共保险的婴儿插管风险更高。
- 入院主要原因包括下呼吸道感染(99.0%)和呼吸暂停或心动过缓(12.8%)。
研究设计与关键结果
- 横断面研究,基于公共卫生前瞻性监测登记,纳入美国27个州39家儿童医院共600例婴儿;中位年龄2.6个月(IQR 1.4-6.0),男性361例(60.2%),早产169例(28.9%),无基础疾病487例(81.2%)。
- 入院主要原因:下呼吸道感染594例(99.0%),呼吸暂停或心动过缓77例(12.8%)。
- 143例(23.8%)接受有创机械通气,中位通气时间6.0天(IQR 4.0-10.0)。
- 非插管婴儿最高呼吸支持:经鼻高流量氧疗243例(40.5%),双水平正压通气150例(25.0%),持续气道正压通气52例(8.7%)。
- <3月龄、早产(胎龄<37周)或公共保险的婴儿插管风险更高;原文未报告具体效应量与95%CI。
- 4例(0.7%)接受体外膜氧合,2例死亡;幸存者中位住院时间5天(IQR 4-10)。
- 采用混合效应多因素对数二项回归模型评估插管与人口学因素、胎龄及基础疾病的关联,以医院为随机效应校正中心间异质性。
证据类型、等级与局限
- 证据类型:横断面研究,基于公共卫生前瞻性监测登记。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,研究结果突出表明需要针对所有婴儿的RSV预防干预,以减轻严重RSV疾病的负担。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) and infant hospitalization worldwide.
OBJECTIVE: To evaluate the characteristics and outcomes of RSV-related critical illness in US infants during peak 2022 RSV transmission.
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used a public health prospective surveillance registry in 39 pediatric hospitals across 27 US states. Participants were infants admitted for 24 or more hours between October 17 and December 16, 2022, to a unit providing intensive care due to laboratory-confirmed RSV infection.
EXPOSURE: Respiratory syncytial virus.
MAIN OUTCOMES AND MEASURES: Data were captured on demographics, clinical characteristics, signs and symptoms, laboratory values, severity measures, and clinical outcomes, including receipt of noninvasive respiratory support, invasive mechanical ventilation, vasopressors or extracorporeal membrane oxygenation, and death. Mixed-effects multivariable log-binomial regression models were used to assess associations between intubation status and demographic factors, gestational age, and underlying conditions, including hospital as a random effect to account for between-site heterogeneity.
RESULTS: The first 15 to 20 consecutive eligible infants from each site were included for a target sample size of 600. Among the 600 infants, the median (IQR) age was 2.6 (1.4-6.0) months; 361 (60.2%) were male, 169 (28.9%) were born prematurely, and 487 (81.2%) had no underlying medical conditions. Primary reasons for admission included LRTI (594 infants [99.0%]) and apnea or bradycardia (77 infants [12.8%]). Overall, 143 infants (23.8%) received invasive mechanical ventilation (median [IQR], 6.0 [4.0-10.0] days). The highest level of respiratory support for nonintubated infants was high-flow nasal cannula (243 infants [40.5%]), followed by bilevel positive airway pressure (150 infants [25.0%]) and continuous positive airway pressure (52 infants [8.7%]). Infants younger than 3 months, those born prematurely (gestational age <37 weeks), or those publicly insured were at higher risk for intubation. Four infants (0.7%) received extracorporeal membrane oxygenation, and 2 died. The median (IQR) length of hospitalization for survivors was 5 (4-10) days.
CONCLUSIONS AND RELEVANCE: In this cross-sectional study, most US infants who required intensive care for RSV LRTIs were young, healthy, and born at term. These findings highlight the need for RSV preventive interventions targeting all infants to reduce the burden of severe RSV illness.
参考来源
- Halasa N, Zambrano LD, Amarin JZ, et al. Infants Admitted to US Intensive Care Units for RSV Infection During the 2022 Seasonal Peak. JAMA Netw Open. 2023. PMID: 37581884. doi:10.1001/jamanetworkopen.2023.28950
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。